• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elutia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/4/25 5:00:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email
    0001708527false00017085272025-05-292025-05-29

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 8-K

    ​

    ​

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): May 29, 2025

    ​

    ELUTIA INC.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    Delaware

    001-39577

    47-4790334

    (State or other jurisdiction
    of incorporation)

    (Commission
    File Number)

    (I.R.S. Employer
    Identification No.)

    ​

    20 Firstfield Road

    Gaithersburg, MD 20878

    (Address of principal executive offices) (Zip Code)

    ​

    (240) 247-1170

    (Registrant’s telephone number, include area code)

    ​

    N/A

    (Former name or former address, if changed since last report)

    ​

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

    ​

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

    ​

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading Symbols

        

    Name of each exchange
    on which registered

    Class A Common Stock, $0.001 par value per share

     

    ELUT

     

    The Nasdaq Capital Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☒

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On May 29, 2025, Elutia Inc. (the “Company”) held its annual meeting of stockholders. A total of 29,585,703 shares of the Company’s Class A common stock were present in person or represented by proxy at the meeting, representing approximately 80.9% of the Company’s Class A common stock outstanding as of the April 1, 2025 record date. The voting results for the proposals considered and voted upon at the meeting, each of which were described in the Company’s proxy statement, are as follows:

    Proposal 1 – Election of two Class II directors to hold office until the Company’s annual meeting of stockholders to be held in 2028 and until their respective successors have been duly elected and qualified.

    ​

    ​

    ​

    ​

    ​

    Votes

    FOR

    Votes

    WITHHELD

    Broker

    Non-Votes

    Brigid A. Makes

    19,152,084

    5,806,525

    4,627,094

    C. Randal Mills, Ph.D.

    21,801,664

    3,156,945

    4,627,094

    ​

    Accordingly, the nominees for Class II directors were elected.

    Proposal 2 – Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Votes

    FOR

    Votes

    AGAINST

    Votes

    ABSTAINED

    Broker

    Non-Votes

    29,581,065

    4,458

    180

    -

    ​

    Accordingly, the Company’s stockholders approved Proposal 2 set forth above.

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

     

    ELUTIA INC.

     

     

     

    Date: June 4, 2025

    By:

    /s/ Matthew Ferguson

     

     

    Matthew Ferguson

     

     

    Chief Financial Officer

    ​

    ​

    Get the next $ELUT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

    EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibiotic bioenvelope choice in cardiac implantable electronic device procedures, delivering robust revenue growth and expanding access through national group purchasing organization

    8/14/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

    GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13754773 Please log in approximately 10 minutes prior to the scheduled start time.

    7/31/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award

    GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been awarded the Medical Device Innovator Award by the Washington Business Journal. This award recognizes Dr. Williams' groundbreaking contributions to the medical device industry, particularly her leadership in the development and successful commercialization of EluPro™, the world's first FDA-cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices (CIEDs). "I am incredibly honored and humbled to receive this prestigious award,"

    7/31/25 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Mills C Randal converted options into 22,473 shares and covered exercise/tax liability with 8,019 shares, increasing direct ownership by 5% to 321,167 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    6/24/25 5:00:06 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,461 shares, increasing direct ownership by 2% to 350,417 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    6/12/25 5:00:16 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT AND CEO Mills C Randal converted options into 27,084 shares and covered exercise/tax liability with 9,664 shares, increasing direct ownership by 6% to 306,713 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    6/12/25 5:00:09 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    SEC Filings

    View All

    SEC Form 10-Q filed by Elutia Inc.

    10-Q - ELUTIA INC. (0001708527) (Filer)

    8/14/25 5:00:54 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELUTIA INC. (0001708527) (Filer)

    8/14/25 4:11:33 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ELUTIA INC. (0001708527) (Filer)

    6/4/25 5:00:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elutia Inc.

    SC 13G - ELUTIA INC. (0001708527) (Subject)

    10/15/24 6:59:31 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

    SC 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/20/24 12:03:03 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    View All

    Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

    SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

    7/31/24 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Financials

    Live finance-specific insights

    View All

    Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

    EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibiotic bioenvelope choice in cardiac implantable electronic device procedures, delivering robust revenue growth and expanding access through national group purchasing organization

    8/14/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

    GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13754773 Please log in approximately 10 minutes prior to the scheduled start time.

    7/31/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

    SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

    5/1/25 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/13/25 4:30:13 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/13/25 4:28:27 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

    4/A - ELUTIA INC. (0001708527) (Issuer)

    2/20/24 12:27:11 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care